Literature DB >> 18358794

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients.

Helle Krogh Johansen1, Samuel M Moskowitz, Oana Ciofu, Tacjana Pressler, Niels Høiby.   

Abstract

BACKGROUND: Colistin resistant Pseudomonas aeruginosa have rarely been reported in cystic fibrosis (CF) patients.
METHODS: We performed a 17-year prospective study on colistin susceptibility and compared our findings with clinical variables.
RESULTS: The first outbreak started in 1995 and lasted 5 years. It involved 27 CF patients who had inhaled colistin twice daily for a median of 10 years. Colistin resistant isolates persisted in individual patients for a median of 75 days after colistin was withdrawn. A second outbreak started in 2004. It involved 40 patients, 17 of whom were the same as in the first outbreak. Most resistant isolates belonged to two major clones that had similar genotypes in the two outbreaks. The P. aeruginosa isolates were all non-mucoid and they appeared in a group of chronically infected patients that had been admitted to the same ward for antibiotic treatment and had been followed at the same week-days in the outpatient clinic. Patients were individually isolated to avoid cross-infection and colistin inhalation was avoided in the CF outpatient clinic and in the ward after both outbreaks. Since 2004, no further spread has been observed.
CONCLUSION: It is important that the colistin resistant clones do not spread to non-infected patients since colistin is an important antibiotic for eradication of initial and intermittent P. aeruginosa colonisation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358794     DOI: 10.1016/j.jcf.2008.02.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  49 in total

1.  Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa.

Authors:  Veerle Liebens; Valerie Defraine; Wouter Knapen; Toon Swings; Serge Beullens; Romu Corbau; Arnaud Marchand; Patrick Chaltin; Maarten Fauvart; Jan Michiels
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.

Authors:  C A Colque; A G Albarracín Orio; S Feliziani; R L Marvig; A R Tobares; H K Johansen; S Molin; A M Smania
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.

Authors:  Stephanie J Wallace; Jian Li; Roger L Nation; Richard J Prankerd; Ben J Boyd
Journal:  J Pharm Sci       Date:  2012-05-23       Impact factor: 3.534

4.  Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Authors:  Samuel M Moskowitz; Elizabeth Garber; Yunhua Chen; Sarah A Clock; Setareh Tabibi; Amanda K Miller; Michael Doctor; Lisa Saiman
Journal:  J Antimicrob Chemother       Date:  2010-04-29       Impact factor: 5.790

5.  Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Authors:  Shaoning Wang; Shihui Yu; Yuwei Lin; Peizhi Zou; Guihong Chai; Heidi H Yu; Hasini Wickremasinghe; Nivedita Shetty; Junhong Ling; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-08-09       Impact factor: 4.200

6.  Whole-genome sequence of Chryseobacterium oranimense, a colistin-resistant bacterium isolated from a cystic fibrosis patient in France.

Authors:  Poonam Sharma; Sushim Kumar Gupta; Seydina M Diene; Jean-Marc Rolain
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

7.  Quinolone-resistant clinical strains of Pseudomonas aeruginosa isolated from University Hospital in Tunisia.

Authors:  Mouna Ben Nejma; Olfa Sioud; Maha Mastouri
Journal:  3 Biotech       Date:  2017-11-13       Impact factor: 2.406

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.

Authors:  Alina D Gutu; Nicole Sgambati; Pnina Strasbourger; Mark K Brannon; Michael A Jacobs; Eric Haugen; Rajinder K Kaul; Helle Krogh Johansen; Niels Høiby; Samuel M Moskowitz
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  V Waters; J E A Zlosnik; Y C W Yau; D P Speert; S D Aaron; D S Guttman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-29       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.